RxDoctor Payments Data

Oscar Gutierrez-Vizuet, MD

General Practice · Laredo, TXNPI 1235168014

Payments from drug & device makers

$414in general payments, 2019–2025

Across 17 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$137
  • Lilly USA, LLC$135
  • Amarin Pharma, Inc.$95
  • Abiomed$31
  • Merck$16

What the payments were for

  • Food & beverage$414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen3$137
Lilly USA, LLC6$135
Amarin Pharma, Inc.5$95
Abiomed2$31
Merck1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$414 in reported general payments places this provider in the 65th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas

Medicare billing

Part B allowed, 2024
$141,054
Medicare patients
237
Services billed
3,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$89,316
JanuviaSitagliptin Phosphate49$52,036
EliquisApixaban51$33,659
MounjaroTirzepatide12$16,747
JanumetSitagliptin Phos/Metformin Hcl13$16,400
FarxigaDapagliflozin Propanediol19$15,141
TradjentaLinagliptin17$14,370
MyrbetriqMirabegron13$13,231
SymbicortBudesonide/Formoterol Fumarate29$7,265
Celecoxib82$6,544
Atorvastatin Calcium737$4,668
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$4,114
Levocetirizine Dihydrochloride217$4,085
Glipizide-MetforminGlipizide/Metformin Hcl73$4,030
Diclofenac Sodium61$3,912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$16$68,43762 claims
Lilly USA, LLCMounjaro, Humulin N, Olanzapine$135$20,61278 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,074 general practice providers in Texas.

Other general practice in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →